FDA Clinical Trials Need More Flexibility, Lawmakers Say
Members of a House Energy and Commerce subcommittee on Wednesday called for the U.S. Food and Drug Administration to revamp its requirements for late-stage clinical drug trials, saying the agency needs...To view the full article, register now.
Already a subscriber? Click here to view full article